

Canadian Biotech Bench Strength Devoted to Taking Canada *Beyond Moose and Mountains*, and into the economy of the future

Ottawa (Jun. 18, 2010) – At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECCanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an **\$84 billion bio-economy**.

The cross-sectoral team comes from companies across the country involved in industrial, agricultural, and health biotechnology including: crop DNA modification, animal health technologies, vaccines, oncology, cardiology, HIV/AIDS, depression, blood diseases, chronic pain, diabetes, and a range of serious conditions. The following new directors joined the board:

- **Michel Fortin**, President & CEO, Prevtect Microbia, Montreal
- **Greg Gubitz**, Senior Vice President, Corporate Development & General Counsel, Biovail Corporation, Mississauga
- **Ed Gudaitis**, General Manager, Gilead Sciences Canada, Mississauga
- **Doug Janzen**, President & CEO, Cardiome Pharma Corp., Vancouver
- **Ron Keefe**, President & CEO, BioVectra Inc., Charlottetown
- **Mark Lievonen**, President, Sanofi Pasteur Limited, Toronto
- **Greg Penner**, President & CEO, NeoVentures Biotechnology, London
- **Andrew Potter**, CEO & Director, VIDO-InterVac, University of Saskatchewan, Saskatoon
- **Wayne Quigley**, President & General Manager, Bristol-Myers Squibb Canada, Montreal
- **Lyndal Walker**, Vice President & General Manager, Abraxis BioScience Inc., Mississauga

With a mandate to develop Canada's biotechnology industry, the Board of Directors leads the association in implementing the recommendations of the industry strategy, *Beyond Moose and Mountains*. The strategy focuses on building Canada's business and regulatory environment; increasing access to capital; and ensuring human resource needs are met – all as biotechnology is poised to lead economic growth in Canada's energy, natural resource, agriculture, and health sectors. More information on this initiative is available at: www.beyondmooseandmountains.ca

"The association is pleased to welcome these knowledgeable leaders, whose recognized achievements within the industry will bring formidable expertise to our board," said Chair of the Board, Brad Thompson, President and CEO of Calgary's Oncolytics Biotech Inc. "BIOTECCanada would also like to thank retiring board members for their service and dedication to the industry. Our volunteer Board of Directors is an active group with expertise across all sectors of biotechnology, representing both small and large biotechnology companies in Canada."

"The Association has been a key leader on critical industry files including market access for biologics, and biotech product pricing in 2009. As a board member I look forward to taking part in shaping the continued growth of Canada's bio-economy," said Doug Janzen, President and CEO of Vancouver's Cardiome Pharma Corp.

"As we face a new wave of technological innovation across agri-business and industrial and environmental biotechnologies, I am pleased to join this pan-Canadian group of industry leaders in raising awareness of the value our technologies bring to Canada's future," said Greg Penner, President and CEO of NeoVentures Biotechnology, an innovative agricultural biotechnology firm from London, Ontario.

"Continued collaboration and dialogue between industry, public health, research organizations and universities remains critical to driving Canada's vaccine adoption and continued development," said Andrew Potter, CEO and Director of the Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac). "I look forward to collaborating with fellow board members on growing our immunization potential."

Contact: Kasia Majewski, Tel: 613-230 5585 x 257, Cell: 613 219 2770, kasia.majewski@biotech.ca

...2



Brad Thompson, President & CEO, Oncolytics Biotech Inc. (Chair)
Luc Mainville, President & CEO, LAB Research Inc. (Vice-Chair)
Brian Lewis, General Manager, Genzyme Canada (Treasurer)
Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance (Member at Large)
Peter Brenders, President & CEO, BIOTECanada (Secretary)
Thomas Bailey, CFO, Angiotech Pharmaceuticals Inc.
Jane Clark, National Leader, Life Sciences Industry Group, Gowling Lafleur Henderson LLP
René Douville, Director, RBC Capital Markets
Michel Fortin, President & CEO, Prevtex Microbia Inc.
Greg Gubitz, Senior Vice President, Corporate Development & General Counsel, Biovail Corporation
Ed Gudaitis, General Manager, Gilead Sciences Canada Inc.
John Helou, General Manager, Specialty Care, Pfizer Canada Inc.
Doug Janzen, President & CEO, Cardiome Pharma Corp.
Ron Keefe, President & CEO, BioVectra Inc.
Vince Lamanna, President, Novo Nordisk Canada Inc.
John Langstaff, President & CEO, Cangene Corporation
Mark Lievonen, President, Sanofi Pasteur Limited
Ross MacLachlan, President & CEO, Lignol Energy Corporation
Gordon McCauley, President & CEO, Allon Therapeutics Inc.
Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance
Greg Penner, President & CEO, NeoVentures Biotechnology
Andrew Potter, CEO & Director, VIDO-InterVac, University of Saskatchewan
Wayne Quigley, President & General Manager, Bristol-Myers Squibb Canada Inc.
Yves Rosconi, President & CEO, Theratechnologies Inc.
Andrew Sheldon, President & CEO, Medicago Inc.
Lyndal Walker, Vice President and General Manager, Abraxis BioScience Inc.
Jim Wispinski, President & CEO, Dow AgroSciences Canada Inc.

ABOUT BIOTECanada www.biotech.ca

BIOTECanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations.



